Home Compare IVZ vs MRNA
Stock Comparison · Valuation-led comparison

Invesco vs Moderna: Which Stock Looks Stronger in 2026?

Invesco leads structurally, with valuation as the clearest single gap between the two profiles. Moderna still has the edge on growth, which keeps the comparison from looking entirely one-sided. The market setup is broadly comparable for both — no clear directional signal from price behavior. The market is not adding a decisive signal either way — the structural read carries the weight.

The comparison is based on similar long-term financial trajectories, not sector labels. Both peer scores are relative to the S&P 500 universe, making them directly comparable.

Updated 2026-05-17

Most of the separation is still concentrated in valuation. The overall score gap is 11 points in favour of Invesco Ltd..

Trajectory Similarity
0.65
Moderately similar
Peer-set rank: #4
within Invesco Ltd.'s functional peer set

This pair is matched through long-term financial trajectory similarity within the selected peer universe.

This level of similarity points to a meaningful structural match, though not a tight one.

The strongest overlap appears in capital structure and recent revenue growth.

Similarity drivers
capital structurerecent revenue growth
What reduces the match
margin consistency
How to read the score
0.85–1.00 · Very similar0.70–0.84 · Similar0.55–0.69 · Moderately similarbelow 0.55 · Loose match
Peer-Relative Score
IVZ
Invesco Ltd.
47
Peer-Score
Signal qualitylow
Peer basis: S&P 500
vs
MRNA
Moderna, Inc.
36
Peer-Score
Signal qualitylow
Peer basis: S&P 500

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

Pricing shapes this comparison more than a broad operating gap.

Dimension spread: IVZ vs MRNA Profitability 11 13 Stability 17 17 Valuation 88 30 Growth 73 100 IVZ MRNA
Gap Ranking
#1 Valuation +58
#2 Growth +27
#3 Profitability +2
#4 Stability
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for IVZ and MRNA Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer IVZMRNA Relative valuation Structural strength

Moderna, Inc. still looks cheaper, even though Invesco Ltd. remains structurally stronger.

Valuation position uses Forward P/E and peer-relative valuation score where available.

Entry today — historical context

Where IVZ and MRNA each sit in their own 5-year price and valuation history.

BASED ON 5-YEAR HISTORY IVZ Elevated · above norm 0th 50th 100th 72 pct gap MRNA Lower · below norm 0th 50th 100th 98th 26th
Today MRNA sits in the lower-middle of its own 5-year history (26th percentile), while IVZ sits higher in its own history (98th). Within each stock's own 5-year context, MRNA is at a historically more favourable entry position than IVZ. This reflects entry timing, not which company is structurally stronger — peer-relative analysis is a separate question addressed above.

Describes historical entry positioning only. Descriptive — not investment advice.

Relative Position vs Comparable Companies
Valuation
On valuation, Invesco Ltd. ranks near the top of the group; Moderna, Inc. sits in the weaker half.
Growth
On growth, the same pattern holds: both rank well, but Moderna, Inc. still sits higher.
Valuation — Dominant Gap
IVZ
88
MRNA
30
Gap+58in favour of IVZ

The peer-relative valuation gap is very wide, with the stronger side also looking meaningfully cheaper.

What keeps the gap from being one-sided

Moderna still pushes back on growth by a very wide margin, which keeps the read from becoming one-way.

What this means for the comparison

The valuation edge is decisive, even though current pricing and growth still lean somewhat toward Moderna, Inc..

Explore full peer positioning in AssetNext

Break down the IVZ vs MRNA comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Other comparisons with conflicting dimension signals

Explore how IVZ and MRNA each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.